In a study from the PHOSP-COVID and ISARIC-4C consortia in the UK, researchers have discovered inflammatory processes taking place during what is termed “long COVID.” Long COVID is defined by the World Health Organization (WHO) as the continuation or development of new symptoms for 3 or more months after the initial SARS-CoV-2 infection. It is estimated that 1 in 10 SARS-CoV-2 infections results in long COVID, thus affecting about 65 million people worldwide.
In a study from the PHOSP-COVID and ISARIC-4C consortia in the UK, researchers have discovered inflammatory processes taking place during what is termed “long COVID.” Long COVID is defined by the World Health Organization (WHO) as the continuation or development of new symptoms for 3 or more months after the initial SARS-CoV-2 infection. It is estimated that 1 in 10 SARS-CoV-2 infections results in long COVID, thus affecting about 65 million people worldwide.
A team from the University of Southern Denmark has reported the discovery of a novel triaromatic pleuromutilin antibiotic candidate for the treatment of gram-positive bacterial infections. Hit evaluation and optimization of previously reported drug-like pleuromutilin conjugates with broad antibacterial activity led to the identification of compound [I] as the most potent and easily synthesizable antibiotic lead.
HSN-003839 is a ubiquitin carboxyl-terminal hydrolase 21 (USP21) inhibitor discovered by Beijing Pharscin Innobio Co. Ltd. and being developed as a novel anticancer agent.
Proviva Therapeutics Ltd. scientists hypothesized that both the activation of IL-2 receptor (IL-2R) and the blockade of programmed cell death protein 1 (PD-1) are complementary and potentially synergistic as a combination therapy for treating cancer.
Erasmus University Rotterdam has disclosed compounds targeting fibroblast activation protein-α (FAPα) reported to be useful for the diagnosis and treatment of cancer.
Results of preclinical studies with a highly potent KRAS (G12D mutant) inhibitor for the treatment of cancer were recently reported by researchers from Betta Pharmaceuticals Co. Ltd. BPI-501836 displayed higher inhibitory activity at KRAS G12D, when compared to the reference compound (IC50=0.25 and...
Triple-negative breast cancer (TNBC) is an aggressive type of breast cancer with poor prognosis and limited therapeutic options, and it accounts for 15%-20% of female invasive breast cancers.
Recent work at Southern Medical University, Guangzhou, focused on the discovery and synthesis of imidazoquinoline-based Toll-like receptor 7 (TLR7) agonists as potential candidates for the treatment of melanoma.
SARS-CoV-2 could proliferate in the lungs causing severe COVID-19 through a special type of immune cell. A group of scientists from Stanford University observed how this coronavirus infected interstitial macrophages through a CD209 receptor, triggering the inflammatory response observed in...
Researchers from Second Military Medical University PLA (Shanghai) and affiliated organizations announced the discovery and preclinical characterization of novel antifungal small-molecule candidates.
The FDA has granted orphan drug designation to the active ingredient in Soligenix Inc.’s Suvax, a subunit protein vaccine of recombinantly expressed Sudan ebolavirus (SUDV) glycoprotein, for the prevention and post-exposure prophylaxis against SUDV infection. SUDV is a type of ebolavirus for which...
Harmony Biosciences Holdings Inc. has announced an exclusive licensing agreement with Bioprojet Pharma SAS to develop, manufacture and commercialize TPM-1116, a highly potent and selective oral orexin OX2 receptor agonist that will be evaluated for the treatment of narcolepsy and other sleep/wake...
Wound healing is a highly specialized dynamic process for the repair of damaged/injured tissues through an intricate mechanism. Any failure in the normal wound healing process results in abnormal scar formation, and a chronic state which is more susceptible to infections. Researchers from Monash...
Cerevel Therapeutics LLC has described muscarinic M4 receptor agonists reported to be useful for the treatment of pain, sleep disorder, schizophrenia, substance abuse and dependence, drug-induced dyskinesia, Alzheimer’s disease and Parkinson’s disease.
Vanderbilt University has disclosed mGlu5 receptor negative allosteric modulators reported to be useful for the treatment of anxiety, autism spectrum disorders, diabetes, pain, Parkinson’s disease, multiple sclerosis, depression and obesity, among others.
Teijin Pharma Ltd. has entered into an exclusive global licensing agreement with Bioprojet under which Teijin Pharma grants Bioprojet Pharma SAS exclusive worldwide rights to research, develop, manufacture and commercialize an investigational candidate for narcolepsy.
Obesity is a chronic disorder tied to other disorders such as hyperglycemia, type 2 diabetes or cardiovascular disease, among others. Recent findings have suggested that EphB tyrosine kinase receptor and its ligand, ephrin B, may be involved in insulin signaling.
Bladder cancer is among the top 10 malignant tumors, still with a high mortality rate. There is a need for reliable biomarkers for early diagnosis of the disease. Proximity extension analysis (PEA) is a method that uses a quantitative PCR readout to analyze protein levels in plasma in longitudinal...
At a recent meeting on “Research priorities for preventing and treating Alzheimer’s disease and related dementias” (ADRD), convened by the National Academies, one consensus priority on ADRD research was that there needs to be more of it at every stage. Several speakers presented stark numbers on...
Volastra Therapeutics Inc. has entered into partnerships with Microsoft Corp., Function Oncology Inc. and Tailor Bio Ltd. with the goal of expanding the potential use of its KIF18A inhibitors.
Parvus Therapeutics Inc. has entered into an exclusive worldwide collaboration and option agreement with Abbvie Inc. for the development and commercialization of novel treatments for inflammatory bowel disease (IBD), utilizing Parvus’ Navacim...
Entera Bio Ltd. has announced promising pharmacokinetic (PK) results from its collaborative research combining a proprietary long-acting GLP-2 agonist developed by Opko Health Inc. with Entera’s proprietary N-Tab technology.
Nuclear factor erythroid 2-related factor 2 (NRF2) is a master regulator of cytoprotective mechanisms, and the cellular levels of this transcription factor are maintained low under normal conditions via actions of a CUL3-based E3 ligase,...
Asialoglycoprotein receptor 1 (ASGR1) is a transmembrane protein specifically expressed in hepatocytes that plays a key role in maintaining circulating glycoprotein homeostasis.
In a recent study published in PNAS, researchers from the University of Texas Southwestern Medical Center investigated cholesterol-mimetic compounds specifically binding and inhibiting Scap. Their final goal was to understand cholesterol...
Breakthrough medicines, billion-dollar deals, spectacular clinical successes and crushing failures all play a part in biopharma’s dynamic story. Developers make scientific advancements with the potential to change everything, only to face regulatory conundrums and ever-fluctuating markets. BioWorld tracks key events in the fast-moving sector every business day. Now, the BioWorld Insider podcast lets you hear directly from the movers and shakers whose collective work is changing how we all live. Join us each week for a new conversation.